EIM Via the Myolex mScan as an ALS Biomarker
EIM Via the Myolex mScan as an ALS Biomarker
Recruiting · NCT06491732 · Registry updated 2026-04-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| EIM Via the Myolex mScan as an ALS Biomarker | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Not stated | 2026-04-22 | NCT06491732 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Beth Israel Deaconess Medical Center | 161 |
| United States Department of Defense | 319 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Atrium Health Wake Forest Baptist Medical Center | Winston-Salem | United States | 15 |
| Barrow Neurological Institute | Phoenix | United States | 50 |
| Beth Israel Deaconess Medical Center | Boston | United States | 462 |
| Dartmouth Hitchcock Medical Center | Lebanon | United States | 23 |
| Massachusetts General Hospital | Boston | United States | 1 |
| University of Michigan | Ann Arbor | United States | 538 |